Literature DB >> 9565168

Discounting life-years: whither time preference?

D Gyrd-Hansen1, J Søgaard.   

Abstract

If elicited time preferences are to be incorporated into economic evaluations, not only social but also individual preferences may be included. The view of this paper is that social intertemporal preferences should govern social intertemporal choices when prioritising between the saving of lives now or in the future. However, the present value of an individual's stream of future health benefits is a matter of private consumption and hence either individual time preferences or social interpersonal preferences could be applied when evaluating the value of extended life or improved quality of life. This paper shows that it is possible to incorporate both types of time preferences in an economic evaluation; using the individual time preference or the social interpersonal preference when discounting the remaining life expectancy and the social intertemporal time preference for discounting the health benefits from the time of the risk reduction to present time. Such a scenario could solve potential problems such as double discounting of QALYs, the paradox of intertemporal equity versus interpersonal equity, as well as include elements of quantity, risk and uncertainty which are otherwise ignored in evaluations of life-saving therapies.

Mesh:

Year:  1998        PMID: 9565168     DOI: 10.1002/(sici)1099-1050(199803)7:2<121::aid-hec318>3.0.co;2-h

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  9 in total

Review 1.  The cost to society of smoking cessation.

Authors:  D Cohen; G Barton
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 2.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.

Authors:  Jasper M Bos; Philippe Beutels; Lieven Annemans; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  J M Bos; Maarten J Postma; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Willingness to pay for a QALY: theoretical and methodological issues.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events.

Authors:  Nabihah Tayob; Susan Murray
Journal:  Biostatistics       Date:  2014-04-08       Impact factor: 5.899

7.  Nonparametric restricted mean analysis across multiple follow-up intervals.

Authors:  Nabihah Tayob; Susan Murray
Journal:  Stat Probab Lett       Date:  2016-02-01       Impact factor: 0.870

8.  Using discounting biases, risk characteristics, and perceived control improves preventive programs.

Authors:  Monica Ortendahl
Journal:  Int J Biomed Sci       Date:  2007-06

9.  Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment.

Authors:  Erik Berglund; Ragnar Westerling; Johan Sundström; Per Lytsy
Journal:  BMC Med Inform Decis Mak       Date:  2018-11-20       Impact factor: 2.796

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.